belimumab, Benlysta (cont.)

Pharmacy Author:
Medical and Pharmacy Editor:

One type of immune cell that is involved in the immune attack in SLE is the B-cell. One of the functions of B-cells is to produce antibodies, proteins that the body usually produces to fight infection. The B-cells in SLE produce antibodies that may be involved in the autoimmune attack in SLE. Belimumab blocks the action of B-cell (lymphocyte) stimulator (BLyS) protein, which B-cells require for survival. By blocking BLys, belimumab reduces the number of B-cells available to produce antibodies that contribute to SLE. In clinical studies, belimumab-treated patients experienced less activity of their SLE than those who received other SLE therapies. Belimumab was approved by the FDA in March 2011.

PRESCRIBED FOR: Belimumab is used for the treatment of adults with active, antibody-positive SLE who are receiving other treatments for SLE. It has not been evaluated in patients with severe active inflammation of the kidney (nephritis) or the central nervous system (brain and spinal chord).

SIDE EFFECTS: The most common adverse reactions of belimumab are:

Other important side effects of belimumab include:

Medically Reviewed by a Doctor on 6/17/2015

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.

Back to Medications Index

Health Solutions From Our Sponsors